Clearmind Medicine Inc. announced that it has successfully manufactured batches of its drug candidate, MEAI-based molecule CMND-100, for use in its first in-human clinical trial. The trial will evaluate the psychedelic-derived drug candidate for the treatment of Alcohol Use Disorder (AUD). The drug candidate was produced under GMP (Good Manufacturing Process) conditions to comply with FDA requirements.